Ignite Creation Date:
2024-05-06 @ 1:21 AM
Last Modification Date:
2024-10-26 @ 11:02 AM
Study NCT ID:
NCT01781052
Status:
COMPLETED
Last Update Posted:
2017-12-04
First Post:
2013-01-22
Brief Title:
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
DAILY Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DAILY
Brief Summary:
This prospective non-interventional multi-center study documents observational data on subjects under routine treatment of Pulmonary Arterial Hypertension functional class III with inhaled Iloprost administered with I-Neb AAD Adaptive Aerosol Delivery device The observation period for each subject covers a one year treatment period with inhaled Ventavis For each subject the investigator or a delegate collects data as defined in the case report form at an initial visit routine follow-up visit at 6 months and final visit at 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VE1210FR | OTHER | None | None |
| 201100416 | OTHER | Company internal | None |